Clinical trials located in

Memmingen

Memmingen city is located in Germany. Currently, 9 clinical trials are being conducted in this city.

Memmingen, nestled in Bavaria, Germany, boasts a rich history dating back to the Roman era. This picturesque city, encircled by remnants of medieval walls, is renowned for its well-preserved old town. Memmingen played a pivotal role in the Peasants’ War of 1525 and was a key site for the proclamation of the Twelve Articles, considered the first draft of human rights in Europe. The city’s architecture, including the grand St. Martin’s Church and the Renaissance-style Town Hall, reflects its storied past. Memmingen also serves as a gateway to the scenic Allgäu region.

  • CT-EU-00054021

    Improving psoriasis treatment for patients: a study on brodalumab

    This detailed study focuses on individuals with moderate-to-severe plaque psoriasis who weigh more than 120 kg. It aims to find out if adjusting the dose of the medication brodalumab can lead to better skin health. In this study, participants receive either an adjusted higher dose of brodalumab or the standard dose. Researchers closely monitor the skin’s response to the treatment, checking if the adjusted dose leads to better skin clearance, meaning fewer or no psoriasis symptoms.

    • Brodalumab
  • Study on ruxolitinib cream for hand eczema

    This study investigates the use of ruxolitinib cream for adults with chronic hand eczema, a skin condition causing itchy, red, and cracked skin on the hands. The cream is applied directly to the affected areas twice daily for 16 weeks. Participants in the study, who are adults with moderate to severe hand eczema, are either given ruxolitinib cream or a placebo cream. After 16 weeks, all participants can choose to continue with ruxolitinib cream for another 16 weeks. The study aims to find out if this cream can effectively reduce the symptoms of hand eczema, like itchiness and skin pain, and improve overall skin condition and quality of life. Around 180 people are taking part in this study, which doesn’t include healthy volunteers​.

    • Ruxolitinib cream
    • Vehicle
  • Examining povorcitinib for treating hidradenitis suppurativa

    This study is about a drug called Povorcitinib, also known as INCB054707. It’s being tested on people who have moderate to severe Hidradenitis Suppurativa (HS), a painful skin condition. The trial will last for 12 weeks, and then there will be an extension period of 42 weeks. The aim of the trial is to see whether the drug is both safe, and effective enough to reduce the symptoms by at least 50%, without increasing certain symptoms like abscesses or tunnels formed by the disease. The study will also look at whether the drug significantly reduces skin pain and improves quality of life.

    • povorcitinib
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Studying povorcitinib safety and effects on nonsegmental vitiligo

    This trial studies the effectiveness and safety of povorcitinib for nonsegmental vitiligo. Participants will receive Povorcitinib or a placebo for 52 weeks. The study aims to see if Povorcitinib can significantly improve vitiligo symptoms on the face and body. It’s open to adults with a clinical diagnosis of nonsegmental vitiligo. Safety, side effects, and treatment efficacy are key focuses, aiming to advance vitiligo treatments and care.

    • povorcitinib
  • Study of Early Breast Cancer Using Camizestrant or Hormone Therapy for Patients at Risk of Recurrence After At Least 2 Years of Standard Therapy

    The clinical trial focuses on patients with early-stage ER+/HER2- breast cancer, meaning the cancer is hormone-receptor-positive (ER+) and does not have an excess of the HER2 protein (HER2-). Participants must have an intermediate or high risk of disease recurrence and must have completed definitive locoregional therapy (such as surgery or radiotherapy) and at least 2 years but not more than 5 years of standard hormone therapy.

    The aim of the study is to assess the efficacy and safety of the drug Camizestrant (AZD9833) compared to standard hormone therapy, which may include aromatase inhibitors (e.g., letrozole, anastrozole, exemestane) or tamoxifen.

    Key measures will include the time to the recurrence of invasive breast cancer, invasive disease-free survival, distant relapse-free survival, overall survival, and the safety of the therapies used.

    Both women and men over 18 years old who meet specific criteria can participate in the study. Therapeutic effects and potential side effects will be monitored during the treatment. Patients will be observed for 10 years from the time of randomization into one of the study groups.

    • camizestrant
    • Anastrozole
    • Letrozole
    • Exemestane
    • tamoxifen
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Germany:

.